Biogen Idec

Monday, September 10, 2012, I started Stock-Trak, an online portfolio game. Stock- Trak allowed me to gain hands on experience testing different investment strategies in a risk-free, yet realistic environment. From September 10 to November 16, 2012, I took part in one such simulation by managing an online Stock-Trak portfolio. I was given an initial amount of $100,000 pretend cash with which to invest. All monetary decisions were at my discretion. This paper discusses my trading experience , my portfolio’s

I.Introduction A. Personal Story about mother and brother B. Information about beta thalassemia 1. Common in people of African, Mediterranean, Asian and Middle Eastern descent 2.Thalassemia is the most common genetic disorder worldwide with beta thalassemia has the most common of the group due to the more than 250 mutations in hemoglobin beta have been linked to causing Beta thalassemia (according to the DNA Learning Center) II.What is Beta Thalassemia? A. Beta thalassemia is a genetic disorder

www.PharmExec.com PHARMACEUTICAL EXECUTIVE Pharma 50 ELECTRONICALLY REPRINTED FROM JUNE 2014 A Pharma 50 Insight: The Accelerating Growth of Specialty Markets By Waseem Noor and Michael Kleinrock, IMS Rank 1 2 3 4 5 6 7 8 9 10 Company headquarters [website] Photo: Thinkstock highlight of the Pharma 50 ranking over the last few years is the steady upward trajectory of companies with a strong franchise in specialty medicines. Specialty markets are appealing to companies that have a strong

| Ethics in Corporate Society | | PHARMACEUTICAL MARKETING-the growing ethical concern? Analytical Report | | | Madiha Raza Noama Naeem Sheikh Zargham Zaigham LETTER OF AUTHORIZATION November 5, 2011 Dear Readers, As students of BBA, our course instructor of Ethics in Corporate Society, Ms. Tania Danish authorized us to make a report on the “PHARMACEUTICAL MARKETING-the growing ethical concern?” We were required to make a report in accordance to our learning in the course

Do more, feel better, live longer GlaxoSmithKline Annual Report 2010 Contents Business review P08–P57 Governance and remuneration P58–P101 Financial statements P102–P191 Shareholder information P192–P212 Business review 2010 Performance overview Research and development Pipeline summary Products, competition and intellectual property Regulation Manufacturing and supply World market GSK sales performance Segment reviews Responsible business Financial review 2010 Financial position and resources